This program is intended for NPs and PAs managing patients with atopic dermatitis in dermatology and primary care settings.
The goal of this program is to improve knowledge and competency of primary care and dermatology NPs and PAs regarding the mechanisms of action and the latest efficacy and safety data for emerging agents in AD management and apply this knowledge to personalized treatment selection for patients with AD as these agents become available.
Upon completion of this activity, participants should be able to:
Summarize key clinical trial data regarding the efficacy and safety of emerging agents for the treatment of AD
Incorporate recent efficacy and safety data on emerging therapies into clinical decisions for patients with AD
Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this education activity:
Victoria Garcia-Albea, NP, DCNP
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Victoria Garcia-Albea, NP, DCNP, has no relevant financial relationships to disclose.
Benjamin Ungar, MD
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis, Castle Biosciences, Fresenius Kabi, Pfizer, Sanofi; researcher: Incyte, Pfizer, Rapt Therapeutics.
The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose except Kristine Kucera as noted below.
Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol Myers Squibb, Janssen, LEO Pharma, Novartis, Sun Pharma, UCB.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 17, 2023, through July 16, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacology credit.
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 16, 2024. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.